Sugi Predict

Sugi Predict / Compounds / SCHEMBL2600436

SCHEMBL2600436

SCHEMBL2600436

CC(C)(C)OC(=O)N1C=CCCC1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CTSK P43235 1/20 0.39
▸ HPGD P15428 1/20 0.37
▸ ATM Q13315 2/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ EPHX1 P07099 1/20 0.36
▸ NR1H2 P55055 1/20 0.35
▸ CHRM2 P08172 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ CHRM3 P20309 1/20 0.34
▸ PREP P48147 2/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ GPR119 Q8TDV5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31552232 0.95 HPGD (0.40) USP2SMN1; SMN2CTSKHPGDATM
SCHEMBL31551926 0.93 HPGD (0.42) USP2SMN1; SMN2CTSKHPGDATM
SCHEMBL1601359 0.89 USP2 (0.42) USP2SMN1; SMN2CTSKHPGDMEN1
SCHEMBL795243 0.81 USP2 (0.42) USP2SMN1; SMN2CTSKHPGDMEN1
SCHEMBL16504608 0.79 CYP1A2 (0.34) USP2KMT2ACHRM2CHRM1CHRM3
SCHEMBL188772 0.76 HPGD (0.41) USP2SMN1; SMN2CTSKHPGDATM
SCHEMBL25759298 0.76 ALDH1A1 (0.38) SMN1; SMN2ATMMEN1KMT2A
SCHEMBL15624094 0.75 USP2 (0.51) USP2SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL22657953 0.75 HPGD (0.44) USP2SMN1; SMN2CTSKHPGDATM
SCHEMBL16096089 0.75 USP2 (0.40) USP2SMN1; SMN2CTSKHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0892797-A4 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL MYERS SQUIBB CO (US) 2004-10-20 — — EP claimed
EP-0892797-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-01-27 — — EP claimed
WO-1997030992-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-28 — — WO claimed
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2026-01-20 — — US disclosed
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS INC (US) 2025-11-13 — — US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 — — US disclosed
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-09-11 — — US disclosed
US-20250179093-A1 KRAS MODULATORS ALTEROME THERAPEUTICS, INC. 2025-06-05 — — US disclosed
WO-2025092818-A1 PYRIDINE DERIVATIVE AND USE THEREOF IN MEDICINE 康百达（四川）生物医药科技有限公司 2025-05-08 — — WO disclosed
CN-119930605-A Condensed imidazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-05-06 — — CN disclosed
CN-119930603-A Condensed imidazole derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2025-05-06 — — CN disclosed
CN-101273026-A Indane derivatives as MCH receptor antagonists HOFFMANN LA ROCHE (CH) 2008-09-24 — — CN disclosed
EP-1934199-A2 INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2008-06-25 — — EP disclosed
WO-2007039462-A2 INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 — — WO disclosed
US-20070078165-A1 MCH receptor antagonists BERTHEL STEVEN J 2007-04-05 — — US disclosed
EP-0892797-A4 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL MYERS SQUIBB CO (US) 2004-10-20 — — EP disclosed
EP-1389194-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-02-18 — — EP disclosed
WO-2002088101-A2 INHIBITORS OF BACE VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-11-07 — — WO disclosed
EP-0892797-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-01-27 — — EP disclosed
WO-1997030992-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078165-A1 MCH receptor antagonists MCHR1, MCHR2, MC5R USP2 3033/4885SMN1; SMN2 1651/4885CTSK 4603/4885
US-20250179093-A1 KRAS MODULATORS KRAS, NRAS, HRAS USP2 1013/4885SMN1; SMN2 3622/4885CTSK 2504/4885
US-20250346610-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS USP2 2827/4885SMN1; SMN2 2585/4885CTSK 3632/4885
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS USP2 2827/4885SMN1; SMN2 2585/4885CTSK 3632/4885
US-20250282799-A1 SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS KRAS, NRAS, HRAS USP2 2827/4885SMN1; SMN2 2585/4885CTSK 3632/4885
US-12528828-B2 Substituted pyrido[4,3-d]pyrimidines as KRAS modulators KRAS, NRAS, HRAS USP2 3777/4885SMN1; SMN2 2906/4885CTSK 3724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.